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SIGNIFICANCE
Scratching plays an important role in skin conditions due 
to a vicious itch-scratch cycle. It is known that patients’ 
expectations regarding a treatment can influence itch in 
skin conditions by placebo and nocebo effects. We investi-
gated whether induced and reversed nocebo effects regar-
ding itch also generalize to scratching behavior. Although 
participants scratched more during itch stimuli of higher 
intensity, hardly any nocebo effects, or reversed nocebo ef-
fects, on scratching were found. Potential generalization of 
placebo and nocebo effects from itch to scratching should 
be further investigated to possibly enhance treatments for 
chronic itch in clinical practice. 
Nocebo effects, i.e. reduced treatment effects due to
patients’ negative expectations, play a role in itch. Re-
cent studies have shown that nocebo effects can be 
induced experimentally on itch and also be minimized 
and even turned into the opposite direction, i.e. pla-
cebo effects. It is not known whether these effects ge-
neralize to itch-associated scratching behaviour. The 
aim of this study was to determine whether induction 
and reversal of nocebo effects on itch evoked by elec-
trical and histamine stimuli generalized to scratching. 
Ninety-seven healthy participants were included in the 
study. The manipulation was successful, as during the 
nocebo learning phase, increased scratching responses 
were found for higher intensity compared with lower 
intensity itch stimuli. During the testing phase of in-
duction or reversal of the nocebo effects, however, no 
significant nocebo effects or reversed nocebo effects, 
were found in scratching. Thus, no straightforward ge-
neralization of nocebo effects from itch to scratching 
was found in this laboratory setting. Further investiga-
tion into possible generalization is needed in different 
settings and in patients with chronic itch.
Key words: placebo; nocebo; itch; conditioning; verbal sugges-
tion; scratching.
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Itch and scratching are common symptoms in skin con-ditions such as psoriasis and atopic dermatitis, and can 
cause significant impairment for patients (1). Scratching 
may have an important role in the maintenance and exa-
cerbation of skin conditions due to a vicious itch-scratch 
circle (2, 3). Effects of pharmacological treatments are 
relatively limited and these treatments often have side-
effects (4). Treatment effectiveness may be improved 
by optimizing placebo effects, while minimizing nocebo 
effects (5, 6).
Placebo and nocebo effects are positive and negative 
treatment effects, unrelated to the treatment mechanism, 
which are induced by patients’ expectations of impro-
vement or worsening, respectively (7–9). Placebo and 
nocebo effects are known to contribute to various condi-
tions and symptoms, and have been investigated mainly 
with regard to pain (7). Recent studies have demonstrated 
that placebo effects can reduce levels of itch in healthy 
participants as well as in patients with clinical itch due 
to chronic conditions (5, 6, 10, 11). Moreover, nocebo 
effects, which may play an even more important role 
in clinical practice (8, 12), can amplify itch, and these 
nocebo effects on itch can also be minimized and even 
turned into the opposite direction, i.e. a placebo effect 
(13). Overall, the combination of enhancing placebo ef-
fects on itch and reversing nocebo effects seems to be a 
promising target to further optimize treatment effects for 
itch. In addition, there are indications that placebo and 
nocebo effects on a specific symptom can generalize to 
other modalities or domains (14–19). Thus, nocebo and 
placebo effects associated with itch treatments may also 
generalize to the behavioural domain, by which patients’ 
scratching behaviour (14, 15) may be influenced in a 
negative or positive direction, respectively. 
Studies on contagious itch provide some evidence that 
nocebo-like effects on itch are also seen on scratching be-
haviour. For example, when participants watched videos 
of people scratching compared with control videos, they 
not only reported higher ratings of overall itch, but also 
scratched more frequently, with the largest effects for 
patients with chronic itch (16). However, it is not known 
whether induced nocebo effects on itch also generalize 
to scratching behaviour. 
The aim of this experimental study was to investigate, 
for the first time, whether induced nocebo effects on itch 
(electrically induced) generalize to scratching behaviour 
in healthy participants. As described previously in our 
article focusing on the levels of itch experienced within 
the same experiment (13), participants first learned 
negative expectations about electrical itch stimuli by 
coupling (through conditioning and verbal suggestions) 
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a certain cue with increased intensities of itch. Next, 
participants were randomized to either the experimental 
group in which the cue was coupled with lowered itch 
intensities (positive expectation induction) or one of 
the control groups in which either negative expectation 
induction with the increased intensities of itch continued, 
or no expectations were induced and only itch stimuli of 
medium intensity were applied (extinction) (13). 
The current study focuses on the behavioural out-
come of scratching. It was hypothesized: (i) that itch 
amplification by nocebo effects would generalize to 
enhanced scratching, and (ii) that subsequent reversion 
of the nocebo effects on itch into placebo effects would 
generalize to decreased scratching. In addition, this 
study exploratively investigated whether reversion of 
the nocebo effects on itch also generalized to scratching 
associated with an additional itch stimulus (histamine 
iontophoresis). Frequency of localized scratching was 
the primary outcome measure, in line with a previous 
study on evoked itch (17). Frequency of total-body scrat-
ching was the secondary outcome measure (16, 18–20). 
Exploratory, we also analyzed duration of localized and 
total-body scratching. 
MATERIALS AND METHODS
The design and methods have been described in full previously, 
in our article focusing on reversing nocebo effects in self-reported 
itch (13). A brief summary is given below.
Participants
A total of 129 healthy participants were included in the study 
(mean ± standard deviation (SD) age 20.3 ± 2.5 years; 78.7% wo-
men). Inclusion criteria were: age range 18–35 years, and fluency 
in the Dutch language. Exclusion criteria were: severe physical 
morbidity (e.g. skin disease, diabetes mellitus, multiple sclerosis), 
psychiatric disorders, chronic itch or pain, diagnosis of histamine 
hypersensitivity, regular use of medication in the last 3 months, use 
of a pacemaker, colour blindness, and pregnancy. The study was 
approved by the medical ethics committee of the Leiden University 
Medical Center in Leiden, the Netherlands (Commissie Medische 
Ethiek). All participants provided written informed consent and 
were reimbursed for their participation.
Study design
The study followed a balanced (1:1:1) randomized controlled, 
multi-arm parallel-group, double-blind design comprising 3 ex-
perimental parts (see Fig. 1 for an overview of the experimental 
study parts). In Part 1, negative expectations were induced regar-
ding electrical itch stimuli (induction of nocebo effect). In Part 2, 
participants were randomized over 3 groups in which they received 
either a positive expectation induction (induction of placebo ef-
fect; group 1; n = 33), a continued negative expectation induction 
(induction of nocebo effect; group 2; n = 34), or an extinction 
procedure (extinction; group 3; n = 30) with regard to electrical 
itch stimuli. Both Parts 1 and 2 comprised a learning phase and a 
testing phase, in which itch stimuli were accompanied by visual 
cues on a computer screen, i.e. purple and yellow coloured circles. 
By randomization it was determined whether the conditioned cue 
was purple or yellow and the neutral cue, consequently, yellow or 
purple. The following assumes that the conditioned cue is purple 
and the neutral cue is yellow. In the learning phase of Parts 1 and 2, 
participants were told that a purple cue would indicate the activa-
tion of the third (sham) electrode that increased (nocebo groups) 
or decreased (placebo groups) the intensity of the itch stimulus. 
They were also told that the yellow cue would indicate deactiva-
tion of the third electrode so the itch stimulus would remain at 
medium intensity. Conditioning was achieved by applying high 
(nocebo groups) or low (placebo group) itch stimulus intensities, 
along with the purple cue (i.e. conditioned trials; 10 stimuli) and 
medium itch stimulus intensities along with the yellow cue (i.e. 
neutral trials; 6 stimuli). During the testing phases of Part 1 and 
2, all stimuli were given at medium intensity (8 stimuli), while 
displaying either the purple or yellow cue (both 50% of the trials). 
In the third part histamine was applied along with the same cue as 
was used for conditioning in Part 2 (see Fig. 1).
Itch stimuli
Electrical itch induction. A constant current stimulator (Isolated 
Bipolar Constant Current Stimulator DS5, Digitimer, Welwyn 
Garden City, UK) was used to induce itch to the inner side of the 
non-dominant wrist through 2 surface electrodes. A third (sham) 
electrode functioned as placebo. Three intensities of itch were 
individually determined (i.e. low, medium, and high). For the 
exact procedure see (10). Previous research indicated that itch was 
the predominant sensation with this induction, and significantly 
higher than pain (21). 
Histamine iontophoresis. Using disposable iontophoresis elec-
trodes (Iogel, Chattanooga, Hixson, TN, USA), 0.6% histamine 
(as diphosphate) (22) solution (in which histamine content is 
comparable to 1% histamine dihydrochloride) was delivered 
with a dose controller (Chattanooga Ionto, Chattanooga) for 2.5 
min at a current level of 0.4 mA to the dominant forearm (for the 
exact procedure see (10)).The same sham electrode used during 
electrical stimulation served as placebo. 
Video-camera and coding software
A video-camera (Panasonic HC-V700, Panasonic Corporation, 
Osaka, Japan) was located left front of the participant in order to 
record participants’ scratching behaviour. A mirror was located at 
the right side of the participant to capture an image of the entire 
body. An event logging software program (The Observer XT 12, 
Noldus Information Technology bv, Wageningen, The Nether-
lands) was used to code the scratching responses (see “Coding of 
scratching behaviour”, below).
Procedure
Potential participants were screened for eligibility using online 
self-report screening questionnaires (Qualtrics, Provo, USA) on 
demographic variables, and physical and psychological conditions 
(see (13)). In advance of the laboratory visit, participants were 
asked to refrain from taking any medication, alcohol, and drugs 
for at least 24 h before the testing, and from smoking cigarettes 
or drinking coffee, tea, cola, or energy drinks at least 2 h before 
testing. At the laboratory visit, the procedures were explained to 
the participant and informed consent was obtained. Participants 
were informed that they were being videotaped, although they were 
given the cover story that the recordings were used for training 
purposes. Baseline itch, pain, and fatigue were obtained using 
numerical ratings scales (NRSs) ranging from 0.0 (no itch/pain/
fatigue at all) to 10.0 (most itch/ pain/fatigue ever experienced). 
After this, the 3 intensities for electrical itch stimulation (i.e. low, 
medium, and high) were individually determined (see “Electrical 
itch induction”). 
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In Part 1, negative expectations regarding electrical itch stimuli 
were induced (induction of nocebo effect, see also Fig. 1). In 
Part 2, participants were allocated randomly to 1 of 3 groups (see 
Fig. 1). In the positive expectation induction group (induction of 
placebo effect; group 1), expectations of low and medium levels 
of itch were raised in the participants. Thus the meaning of the 
colour of the conditioned cue was reversed compared with Part 1. 
In the negative expectation induction group (induction of nocebo 
effect; group 2), exactly the same nocebo procedure was applied 
as in Part 1. In the extinction group (extinction; group 3) all stimuli 
were applied at medium intensity and no verbal suggestion was 
provided. Participants were merely told that several stimuli would 
be applied again, accompanied by purple or yellow cues, without 
being given further details. In Part 3, for all participants, histamine 
iontophoresis was applied at the same intensity. The verbal sug-
gestions corresponded with those provided in Part 2. Between the 
stimuli there were standardized inter-stimulus intervals and during 
the experimental session several standard breaks (13).
Participants were informed 4 times that they were allowed to 
scratch their itch freely at any time: 3 times during the session with 
electrical itch stimulation (before determining the individual itch 
thresholds; before the start of Part 1; and before the start of Part 
2) and once before the start of histamine iontophoresis. 
At the end of the experiment, participants rated the levels of 
pain that were induced overall by the electrical itch stimuli on 
an NRS from 0.0 to 10.0 with a mean ± SD of 1.0 ± 1.2. Finally, 
saliva was collected for DNA analysis (the results will be reported 
elsewhere) and participants were asked about their impression 
of the goal of the study. Almost all participants did not know the 
true goal of the study.
Coding of scratching behaviour
Spontaneous scratching was coded using the video-recordings 
by an independent rater who was unaware of the participant’s 
allocation to 1 of 3 groups and the colour of the conditioned and 
neutral cue. Scratching was defined as any skin contact movement 
that could reduce itch, e.g. typical scratching using the finger-
nails, picking with fingernails, or rubbing, while not taking into 
account touching (16, 20). Regarding the electrical itch stimuli, 
scratching behaviour was coded from the start of an itch stimulus 
up to the next trial (up to 2 min) for the learning and testing pha-
ses separately. For the histamine stimulus, scratching behaviour 
was coded for the 2.5-min duration of the stimulus. Scratching 
responses were mapped spatially: (i) strictly localized (up to 5 cm 
around the electrodes); (ii) extended localized on the stimulated 
arm, excluding strictly localized areas; (iii) extended other arm; 
(iv) extended head/face/neck; (v) extended torso; and (vi) exten-
ded legs. For the preparation of the variables for the analyses, a 
distinction was made between localized (areas 1 and 2 together) 
(17) and total-body scratching (areas 1–6 together) (16, 18, 19, 
20). Using The Observer software program (The Observer XT 1), 
frequency (primary outcome) and duration (explorative outcome) 
of scratching were calculated separately for the different cues and 
the testing and learning phases. 
Statistical analysis 
Of the 129 participants tested, data for 97 could be included in the 
analyses, as 32 were excluded from data analysis on the basis of 
several pre-determined criteria (see (13)). Specifically, for 8 par-
Fig. 1. Experimental design. In part 1, negative expectations were induced: participants were told that the purple cue (conditioned cue) indicated 
an increase in the itch stimulus, and that the yellow cue (neutral cue) indicated no change in the itch stimulus. In accordance, the purple and yellow 
cues were repeatedly paired with high and medium electrical itch stimulus intensities, respectively. In part 2, participants were randomized over the 3 
groups in which: (i) positive expectations were induced; (ii) continued negative expectations were induced; or (iii) an extinction procedure was applied. 
In the learning phases verbal suggestion and conditioning procedures depended on the experimental group. In the testing phases the verbal suggestion 
corresponded to the verbal suggestion provided in the learning phase, while all participants received electrical itch stimuli of medium intensity. In part 3, 
for all participants, histamine iontophoresis was applied at the same intensity. The verbal suggestions corresponded with those provided in Part 2, and 
the purple cue (conditioned cue) was displayed during the histamine application. Note that for half of the participants the conditioned cue was a purple 
cue and the neutral cue a yellow cue (like in this example); for the other half of the participants the conditioned cue was yellow and the neutral purple.
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ticipants data collection had failed and 24 participants were 
excluded (with the permission of the local ethics committee) 
because they experienced no or too little itch after repeated 
electrical itch induction (for details see (13)). However, sen-
sitivity analyses were also carried out for all 121 participants, 
including those in whom levels of evoked itch were low but 
scratching data were available. 
In line with the main aims, for all outcomes, frequency of 
localized scratching was regarded as the primary outcome, 
frequency of total-body scratching was regarded as the se-
condary outcome and duration of localized and total-body 
scratching was analysed exploratively. Means of scratching 
were calculated for both conditioned (i.e. with the supposed 
activation of the third electrode) and neutral trials (i.e. wit-
hout the supposed activation of the third electrode) for the 
learning and testing phases. The nocebo effect on scratching 
was defined as the difference between scratching episodes 
associated with the conditioned trials and neutral trials. The higher 
the score the higher was the nocebo effect. 
To explore the efficacy of the nocebo expectation induction 
procedure during the learning phase in Part 1, scratching episodes 
associated with the conditioned and neutral trials were compared 
in paired samples t-tests. Also, to test the hypothesis that there 
was a nocebo effect on scratching in the testing phase of Part 1, 
paired samples t-tests were performed.
The efficacy of the expectation induction procedure in the 
learning phase of Part 2 was assessed exploratively by univariate 
analyses of variance (ANOVA) with group as between-subject 
factor and scratching as dependent variable. Similar ANOVAs 
were performed for the testing phase of Part 2 when testing the 
hypothesis that the positive expectation induction group would dis-
play a significantly smaller nocebo effect with regard to scratching 
than the control groups (negative expectation induction group and 
extinction group). A similar approach was taken to exploratively 
assess generalization of the reversion of nocebo effects on itch 
to scratching during the histamine stimulus, whilst including the 
scratching scores during histamine iontophoresis. 
Where the assumptions of the statistical tests (e.g. of normality) 
were violated, sensitivity analyses were conducted by calculating 
bias-corrected 95% confidence intervals (95% CIs) around the 
relevant parameter using 1,000 bootstrapping samples (23). This 
was the case for the duration of localized scratching in the testing 
phase of Part 1, as well as the frequency and duration of localized 
scratching behaviour in the testing phase of Part 2. Since bootstrap-
ped confidence intervals around the parameters provided results 
similar to those reported without bootstrapping, we reported the 
non-bootstrapped analyses.
All analyses were performed using SPSS 23.0 for Windows 
(IBM SPSS Statistics, Chicago, IL, USA) and the level of statis-
tical significance was set at p < 0.05 (2-sided). Unless displayed 
otherwise, results are displayed as means ± SD.
RESULTS
In Part 1 (induction of nocebo effect), negative expecta-
tions were induced in all participants. In Part 2 (reversal 
of nocebo effect), randomization of the participants 
across the 3 groups resulted in a total of 33 participants 
in the positive expectation induction group, 34 partici-
pants in the negative expectation induction group, and 30 
participants in the extinction group. The groups did not 
differ significantly on baseline characteristics (Table I).
Induction of negative expectations (Part 1)
Learning phase. During the learning phase of Part 1 
(Table II), in which negative expectations were induced 
for all participants by both verbal suggestion and condi-
tioning, as expected, the paired samples t-tests revealed 
that means for the conditioned trials were significantly 
higher than for the neutral trials for the frequency of 
localized scratching (t(96) = 3.89, p < 0.001, d = 0.395), 
duration of localized scratching (t(96) = 4.13, p < 0.001, 
d = 0.420), and duration of total-body scratching (t(96) 
= 3.07, p < 0.01, d = 0.312). The frequency of total-body 
scratching was marginally significantly higher for the 
conditioned vs. neutral trials (t(96) = 1.94 p = 0.056, 
d = 0.196).
Testing phase. When testing whether there was a nocebo 
effect during the testing phase of Part 1 (Table II), in 
which all stimuli were applied at medium intensity, the 
Table I. Participant characteristics
Group 1 –  
Positive 
expectation 
induction
n = 33
Group 2 –  
Negative 
expectation 
induction
n = 34
Group 3 – 
Extinction
n = 30
Age, years, mean ± SD 20.3 ± 2.6 20.3 ± 2.7 20.0 ± 2.0
Male/female ratio, % 27.3/72.7 23.5/76.5 20.0/80.0
Hormonal contraceptives, % 42.4 50.0 56.7
Itch baseline test day NRS, mean ± SD 0.6 ± 0.8 0.6 ± 0.7 0.6 ± 0.7
Pain baseline test day NRS, mean ± SD 0.4 ± 0.7 0.4 ± 0.5 0.5 ± 0.7
Fatigue baseline test day NRS, mean ± SD 2.4 ± 1.6 2.1 ± 1.5 2.1 ± 1.3
Itch baseline histamine NRS, mean ± SD 1.0 ± 1.1 0.9 ± 1.1 0.7 ± 0.7
Pain baseline histamine NRS, mean ± SD 0.6 ± 1.0 0.6 ± 0.6 0.5 ± 0.7
Fatigue baseline histamine NRS, mean ± SD 3.6 ± 1.7 3.6 ± 1.3 3.8 ± 1.5
SD: standard deviation; NRS: numerical rating scale.
Table II. Mean frequency and duration of scratching episodes in the learning and testing phase in Part 1 (induction of negative expectations)
Learning phase Testing phase
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD p-value d
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD p-value d
Localized scratching Frequency 0.6 ± 0.7 0.4 ± 0.6 < 0.001 0.395 0.3 ± 0.4 0.3 ± 0.4 0.081 0.179
Duration 2.5 ± 4.3 1.8 ± 3.8 < 0.001 0.420 1.1 ± 2.0 0.9 ± 1.7 0.079 0.180
Total-body scratching Frequency 1.9 ± 1.2 1.8 ± 1.0 0.056 0.196 1.7 ± 1.3 1.6 ± 1.2 0.53 0.064
Duration 5.1 ± 5.8 4.3 ± 4.8 < 0.001 0.312 3.7 ± 4.0 3.4 ± 3.9 0.15 0.148
Means and standard deviations (SD) of mean frequency and mean duration (in s) of scratching episodes in the learning and testing phase in Part 1 (induction of negative 
expectations; n=97). Localized scratching episodes comprised scratching limited to the arm where the itch stimulus was applied. Total-body scratching episodes comprised 
scratching over the whole body (including localized scratching).
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paired samples t-test revealed that means for the condi-
tioned trials were marginally significantly higher than 
for the neutral trials for frequency of localized scrat-
ching (t(96) = 1.77, p = 0.081, d = 0.179) and duration of 
localized scratching (t(96) = 1.77, p = 0.079, d = 0.180). 
No significant nocebo effect was found for total-body 
scratching regarding the frequency (t(96) = 0.63, p = 0.53, 
d = 0.064) and duration (t(96) = 1.46, p = 0.15, d = 0.148).
Reversal of nocebo effect (Part 2)
Learning phase. Table III displays the mean ± SD fre-
quency and duration of the scratching episodes evoked 
by the itch stimuli associated with the conditioned and 
neutral trials during the learning phases for each group, 
in which depending on the group, positive (group 1) 
or negative (group 2) expectations were induced or an 
extinction procedure (group 3) was applied. When tes-
ting whether the mean change score (conditioned trials 
minus neutral trials) of scratching episodes was smaller 
in the positive expectation induction group (group 1) 
than in the control groups (groups 2 and 3), ANOVAs 
did not reveal a significant group difference for any of 
the outcome measures: frequency of localized scrat-
ching (F(2,96) = 1.37, p = 0.259 ηp
2 = 0.028), frequency 
of total-body scratching (F(2,96) = 2.09, p = 0.130, ηp
2 
= 0.042), duration of localized scratching (F(2,96) = 1.43, 
p = 0.244 ηp
2 = 0.030) and duration of total-body scrat-
ching (F(2,96) = 0.95, p = 0.391, ηp
2 = 0.020).
Testing phase. Table IV displays the mean ± SD fre-
quency and duration of the scratching episodes evoked 
by the itch stimuli associated with the conditioned and 
neutral trials during the testing phase for each group, 
in which all stimuli were applied at medium intensity. 
When testing the hypothesis that the nocebo effect on fre-
quency of localized scratching was smaller in the positive 
expectation induction group than in the control groups, 
univariate ANOVA showed no significant difference 
in the magnitude of the nocebo effect (F(2,96) = 0.36, 
p = 0.697 ηp
2 = 0.008). Also, for the frequency of total-
body scratching (secondary outcome) no significant dif-
ference between the groups was observed (F(2,96) = 0.90, 
p = 0.409 ηp
2 = 0.019). Furthermore, also regarding dura-
tion of scratching episodes, no significant difference in 
localized scratching (F(2,96) = 0.78, p = 0.463 ηp
2 = 0.016) 
or total-body scratching (F(2,96) = 1.30, p = 0.279 ηp
2 
= 0.027) was found between the groups.
Generalization of revered nocebo effects on itch to 
scratching behaviour for histamine iontophoresis
When exploring scratching behaviour during the hista-
mine stimulus (Table V), ANOVAs showed no significant 
effect of group regarding the frequency of localized scrat-
ching (F(2,96) = 0.62, p = 0.54, ηp
2 = 0.013), frequency of 
total-body scratching episodes (F(2,96) = 0.56, p = 0.57, 
ηp
2 = 0.012), duration of localized scratching episodes 
(F(2,96) = 0.32, p = 0.73, ηp
2 = 0.007), or duration of 
total-body scratching episodes (F(2,96) = 0.25, p = 0.77, 
ηp
2 = 0.005). 
Sensitivity analyses 
When exploring the influence of excluding the data of 
the 24 participants who experienced little to no itch 
Table III. Mean frequency and duration (s) of scratching episodes in the learning phase in Part 2
Group 1 – Positive expectation 
induction 
Group 2 – Negative expectation 
induction Group 3 – Extinction
p-value d
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD
Localized scratching Frequency 0.3 ± 0.4 0.4 ± 0.5 0.3 ± 0.4 0.2 ± 0.3 0.4 ± 0.4 0.4 ± 0.5 0.259 0.028
Duration 0.9 ± 1.2 1.2 ± 1.4 1.1 ± 1.9 1.0 ± 1. 1.5 ± 1.9 1.3 ± 1.8 0.244 0.030
Total-body scratching Frequency 1.7 ± 1.1 1.5 ± 0.9 1.9 ± 1.2 1.6 ± 1.0 1.6 ± 0.9 1.7 ± 0.9 0.130 0.042
Duration 3.8 ± 3.0 3.5 ± 3.0 3.8 ± 2.7 3.3 ± 2.5 3.8 ± 3.9 3.9 ± 4.1 0.391 0.020
Means ± standard deviations (SD) of mean frequency and mean duration (in s) of scratching episodes and for the change in scratching score (scratching frequency/duration 
score of the conditioned trials minus the neutral trials) in the positive expectation induction group (group 1; n = 33), the negative expectation induction group (group 2; 
n = 34) and the extinction group (group 3; n = 30) in the learning phase of Part 2. Localized scratching episodes comprised scratching limited to the arm where the local 
itch stimulus was applied. Total-body scratching episodes comprised scratching over the whole body (including localized scratching).
Table IV. Mean frequency and duration (s) of scratching episodes in the testing phase in Part 2
Group 1 - Positive expectation 
induction
Group 2 – negative expectation 
induction Group 3 – Extinction
p-value d
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD
Conditioned trials
Mean ± SD
Neutral trials
Mean ± SD
Localized scratching Frequency 0.3 ± 0.4 0.3 ± 0.5 0.2 ± 0.3 0.3 ± 0.4 0.3 ± 0.3 0.2 ± 0.3 0.697 0.008
Duration 0.7 ± 1.1 1.0 ± 1.8 0.6 ± 1.0 0.8 ± 1.6 0.7 ± 1.2 0.7 ± 0.9 0.463 0.016
Total-body 
scratching
Frequency 1.4 ± 1.0 1.6 ± 0.9 1.7 ± 1.0 1.7 ± 0.8 1.6 ± 1.0 1.6 ± 0.9 0.409 0.019
Duration 2.5 ± 1.9 3.4 ± 2.5 3.1 ± 2.3 3.3 ± 2.5 3.2 ± 3.3 3.2 ± 2.6 0.279 0.027
Means and standard deviations (SD) of mean frequency and mean duration (in s) of scratching episodes and for the change in scratching score (scratching frequency/
duration score of the conditioned trials minus the neutral trials) in the positive expectation induction group (group 1;  n = 33), the negative expectation induction group 
(group 2; n = 34) and the extinction group (group 3; n = 30) in the testing phase of Part 2. Localized scratching episodes included scratching limited to the arm where 
the local itch stimulus was applied. Total-body scratching episodes included scratching over the whole body (including localized scratching).
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after repeated electrical itch induction (<1 itch on NRS), 
sensitivity analysis with all 121 participants for whom 
scratching data were available generally obtained re-
sults similar to those for the 97 participants, with some 
exceptions. Specifically, in the testing phase of Part 1, 
instead of a marginally significant difference, results 
revealed a significantly higher mean ± SD frequency 
of localized scratching episodes for the conditioned 
trials (0.3 ± 0.4) than for the neutral trials ( 0.2 ± 0.3) 
(t(120) = 2.36 p < 0.05, d = 0.214), and a longer mean du-
ration of localized scratching episodes for the conditio-
ned trials (1.0 ± 1.8) than for the neutral trials (0.8 ± 1.5) 
(t(120) = 2.27, p < 0.05, d = 0.206). In the testing phase 
of Part 2, instead of a non-significant difference, there 
was a tendency towards significance in the magnitude 
of the nocebo effect of duration of total-body scratching 
between the positive expectation induction group and 
the control groups (F(2, 120) = 2.78, p = 0.066, ηp
2 
= 0.045).
DISCUSSION
The present study investigated, for the first time, the 
generalizability of induced nocebo effects on itch to 
scratching behaviour. First, results showed that, while 
manipulating the itch intensity during the nocebo lear-
ning phase, participants scratched more often and for a 
longer duration when itch stimuli of a higher intensity 
were applied than when itch stimuli of medium intensity 
were applied. However, this did not lead to subsequent 
significant nocebo effects on scratching behaviour in 
the testing phase, apart from some marginal significant 
effects. Secondly, reversing nocebo effects on itch by 
positive expectation induction, did not lead to reversed 
or reduced nocebo effects on scratching behaviour. 
Sensitivity analysis in a larger group of participants did 
show some significant nocebo effects on scratching and 
a tendency for reduced nocebo effects on scratching. 
We can conclude that, although higher itch intensity is 
associated with more scratching, no conclusive evidence 
for generalization of nocebo effects on itch to scratching 
was found.
Exposing participants to itch stimuli 
of high intensity (in the learning phase 
of nocebo induction) resulted in signi-
ficantly more frequent scratching, and 
scratching for a longer duration, around 
the specific area of the forearm where 
itch was induced compared with itch sti-
muli of medium intensity. When we as-
sessed scratching behaviour all over the 
body, similar findings were obtained, 
with significant results for duration and 
marginally significant results for fre-
quency of scratching behaviour. Thus, 
when itch stimuli of higher intensity are 
applied compared with itch stimuli of lower intensity, 
participants not only experienced more itch (13), they 
mostly also displayed increased scratching behaviour, in-
dicating a correspondence between self-report outcomes 
and observable behaviour (3, 18). This further supports 
that scratching behaviour can objectively be measured 
and is related to the intensity of itch (16, 18, 19).
Our hypothesis that nocebo effects on itch generalize 
to scratching could not be confirmed. Negative expecta-
tion induction for high levels of itch regarding stimuli 
of medium intensity (in the testing phase of part 1) did 
not result in significant nocebo effects on scratching. 
Also positive expectation induction for low levels of 
itch regarding stimuli of medium intensity (in the testing 
phase of part 2) did not result in significantly smaller 
nocebo effects on scratching for both the electrical and 
histamine stimuli compared with the control groups. 
These findings are unexpected, since our study did 
show significant nocebo effects on self-reported itch 
after negative expectation induction, and significantly 
reduced nocebo effects on itch after positive expectation 
induction when electrical or histamine itch stimuli were 
applied (13). A possible explanation for the non-signi-
ficant results on scratching might be that, in our study, 
no verbal suggestions were provided for scratching, but 
only for itch, which is a pure way to assess generaliza-
bility of the nocebo effects on itch. Similar results were 
obtained in a recent study on itch perception modulated 
by verbal suggestion in healthy participants (24). This 
study demonstrated an increase in itch perception in a 
nocebo-like condition, but no increase in the desire to 
scratch. Actual scratching behaviour was not measured 
(24). Furthermore, in studies regarding contagious itch, 
i.e. itch evoked by audio-visual stimuli, inductions of 
expectation often indirectly address itch and especially 
scratching, e.g. by showing participants videos of people 
scratching (16–18, 20). This is, for example, confirmed 
by a study by Lloyd et al. (19) demonstrating that pic-
tures of itch-relevant stimuli, e.g. insects crawling on 
skin, resulted in increased itch in healthy subjects than 
did pictures of people scratching, whereas pictures of 
people scratching led to more scratching behaviour than 
Table V. Mean frequency and duration (s) of scratching episodes during application 
of histamine 
Group 1 –
Positive 
expectation 
induction 
Mean ± SD
Group 2 – 
Negative 
expectation 
induction 
Mean ± SD
Group 3 – 
Extinction
Mean ± SD p-value d
Localized scratching Frequency 2.6 ± 3.4 1.8 ± 2.5 2.6 ± 3.6 0.54 0.013
Duration 13.8 ± 23.0   9.8 ± 17.6 12.5 ± 22.3 0.57 0.012
Total-body scratching Frequency 3.2 ± 3.5 2.3 ± 2.7 2.7 ± 3.7 0.73 0.007
Duration 14.7 ± 23.3 11.0 ± 18.1 12.6 ± 22.3 0.77 0.005
Means and standard deviations (SD) of mean frequency and mean duration (in s) of scratching episodes 
during the application of the histamine stimulus (which takes approximately 2.5 min) in the positive 
expectation induction group (group 1; n = 33), the negative expectation induction group (group 2; n = 34) 
and the extinction group (group 3; n = 30). Localized scratching episodes included scratching limited to 
the arm where the local itch stimulus was applied. Total-body scratching episodes included scratching 
over the whole body (including localized scratching).
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the itch-relevant pictures (19). Previous studies investi-
gating generalizability of placebo or nocebo effects on 
symptoms other than itch all included verbal suggestions 
for the second modality. For example, a study on pain 
showed that conditioned nocebo effects in pain tolerance 
can be transferred to motor endurance; however, verbal 
suggestions for decreased motor endurance were also 
provided (25). Other studies on pain that demonstrated 
transferable placebo effects from pain to emotion have 
also provided verbal suggestions regarding alleviation of 
negative emotions (26–28). It is likely that the generali-
zed placebo and nocebo effects are partly explained by 
additional verbal suggestions for the second modality. 
Another possible explanation for the lack of generalized 
nocebo effects on scratching in the current study could be 
that the levels of itch did not always reach the threshold 
at which participants felt the urge to scratch (15). Future 
research should investigate whether directly targeting 
scratching behaviour by induction of expectation is re-
quired to induce and reverse nocebo effects on scratching. 
When comparing healthy participants with patients 
with chronic itch conditions, several studies have shown 
that patients scratch more frequently than healthy partici-
pants when an experimental itch stimulus is applied (17, 
20), even when stimulus intensity and self-reported itch 
do not significantly differ for both patients and healthy 
participants (20). This is underlined by neuroimaging 
studies that demonstrate that different brain areas are 
activated in patients with chronic itch and healthy par-
ticipants when itch stimuli are applied (29–31). For ex-
ample, a study in patients with atopic dermatitis showed 
that, even though there were no significant differences in 
perceived itch, brain activation in areas that are assumed 
to correspond to scratching differed between the patients 
and healthy participants (29). Such differences may also 
play a role in placebo and nocebo effects on scratching 
and therefore placebo and nocebo effects on scratching 
should be investigated in patients with chronic itch. 
Some possible limitations and further suggestions for 
future research should be discussed. First, participants 
might have been hindered in spontaneous scratching 
due to the filler tasks that were provided between the 
different itch stimuli. Since the electrodes were attached 
to the non-dominant arm, participants were not able to 
scratch around the itch-induced area of the forearm with 
the non-dominant hand, but only with their dominant 
hand. However, participants mainly used their dominant 
hand for completing the filler tasks and had to pause 
performing the tasks in order to scratch their itch. It is 
possible that this led to reduced scratching in participants. 
Future studies should consider inter-stimulus intervals 
with tasks whereby participants do not use their hand 
and are able to scratch without any constraints. Secondly, 
participants tended to report less itch as the experiment 
progressed (13). It could be that the decline in itch re-
sulted in less often reaching the participants’ itch thres-
hold (15) (especially in the testing phase of Part 1 and 
the learning and testing phase of Part 2), which could 
have influenced the scratching results. Thirdly, since we 
were interested mainly in whether nocebo effects on itch 
generalize to scratching behaviour, we did not directly 
compare localized and extended scratching behaviour 
(such as (17)). Given that, for contagious itch, people do 
not seem to scratch the same area as the area observed 
in the manipulation video (i.e. area on the body where 
the person in the manipulation video scratches), future 
research could manipulate the location of itch to deter-
mine whether nocebo effects on scratching are mainly 
localized or extended. 
In conclusion, this study confirms that scratching 
behaviour can be used as a measure of itch in healthy 
participants. No conclusive evidence was found for the 
generalization of nocebo effects on itch to scratching; 
however, sensitivity analysis in a larger group of parti-
cipants showed some preliminary effects or tendencies 
that nocebo effects on itch can generalize to scratching. 
Future research should investigate generalization of 
(reversed) placebo and nocebo effects from itch to 
scratching, especially when high levels of itch are ex-
perienced, exceeding specific itch thresholds that lead 
to scratching, and also when involving patients with 
chronic itch. From the clinical viewpoint, studying how 
a placebo effect can generalize from one domain to 
another may be important to increase the effectiveness 
of treatments for all kinds of conditions that often com-
prise symptoms in different modalities. The possibility 
of reducing symptoms in one modality, i.e. scratching 
behaviour, using training in another modality, i.e. itch, 
could possibly be applied in dermatological conditions 
associated with chronic itch and scratching. Therefore, 
greater understanding of the generalization of placebo 
and nocebo effects on itch to scratching behaviour could 
be important to determine ways to enhance treatments 
for chronic itch in clinical practice.
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